Search Results

Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm Therapeutics for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.

By allowing compounding pharmacies to produce certain unapproved peptides, the Department of Health and Human Services could, in the short term, put patients in harm’s way. Longer term, the policy shift threatens the industry that brings new medicines to market.

The cessation of manufacturing activities follows a Sun Pharma recall and reports that regulators found fault with the company’s quality system.

Two-year agreement and approximately US$198,000 in potential purchases while opening established UK first-aid, medical-supply, workplace and education channels Highlights • Definitive agreement signed October 28, 2026 appoints Poole Bay Holdings Ltd. as exclusive UK distributor of VIVI Epi™ for an initial 24-month term, subject to UK regulatory requirements. • Contractual minimum purchase to maintain exclusivity. The initial two-year minimum volumes represent approximately US$198,000 in potential purchases. • Poole Bay Holdings reports 20 specialist e-commerce sites and more than 30,000 products, spanning first-aid, medical, health and safety, and workplace supplies. • Poole Bay has a network of 15,000 schools across the UK, and will be providing VIVI Epi to these locations • UK Food Standards Agency research estimates approximately 2.4 million adults have a clinically confirmed food allergy, highlighting the scale of allergy-management needs [1]. • The agreement provides for launch sampling, planned promotional activity and a framework to pursue institutional and consumer channels, subject to registrations and market adoption.

In a mid-stage trial, the lower dose of Tiziana’s intranasal monoclonal antibody reduced microglial activation in a specific type of multiple sclerosis. But the path forward remains unclear after the higher dose failed to deliver the same benefit.